| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/24/2002 | WO2001041785A3 Enzyme treatment for infection |
| 01/24/2002 | WO2001037855A3 Temperature dependent neuronal rescue |
| 01/24/2002 | WO2001036977A8 Identification of disease markers involving mass-based-separation |
| 01/24/2002 | WO2001036470A3 Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides |
| 01/24/2002 | WO2001034768A3 15 human secreted proteins |
| 01/24/2002 | WO2001032910A3 27 human secreted proteins |
| 01/24/2002 | WO2001032711B1 Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof |
| 01/24/2002 | WO2001029221A3 Proteins and polynucleotides encoding them |
| 01/24/2002 | WO2001027276A3 Dna sequences from breast tumor and uses thereof |
| 01/24/2002 | WO2001025436A3 Endozepine-like polypeptides and polynucleotides encoding same |
| 01/24/2002 | WO2001025397A3 Compositions and methods for tumor-targeted delivery of effector molecules |
| 01/24/2002 | WO2001023562A3 Osteoprotegerin regulatory region |
| 01/24/2002 | WO2001023409A8 38 human secreted proteins |
| 01/24/2002 | WO2001019860A3 Proteins associated with cell differentiation |
| 01/24/2002 | WO2001019855A3 Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 01/24/2002 | WO2001016290A3 Dna encoding the human serine protease eos |
| 01/24/2002 | WO2001015511A3 Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses |
| 01/24/2002 | WO2001013908A3 Tissue volume reduction |
| 01/24/2002 | WO2001012856A3 Analysis of sequence tags with hairpin primers |
| 01/24/2002 | WO2001012819A3 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 01/24/2002 | WO2001012654A3 Orally active peptides that prevent cell damage and death |
| 01/24/2002 | WO2001010454A3 Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection |
| 01/24/2002 | WO2001008708A3 Enhanced delivery via serpin enzyme complex receptor ligands |
| 01/24/2002 | WO2001000787A3 Methods of treatment using lig 72a and variants thereof |
| 01/24/2002 | WO2001000679A3 Methods for inducing t cell non-responsiveness to a tissue or organ graft |
| 01/24/2002 | WO2001000655A3 Therapeutic peptides derived from subsequences of bpi |
| 01/24/2002 | WO2000073478A9 Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
| 01/24/2002 | WO2000073453A9 T-bet compositions and methods of use thereof |
| 01/24/2002 | WO2000073338A9 Compositions and methods for the therapy, diagnosis and monitoring of breast cancer |
| 01/24/2002 | WO2000071574A3 Antigenic neisserial peptides |
| 01/24/2002 | WO2000069428A3 Anionic polymers as toxin binders and antibacterial agents |
| 01/24/2002 | WO2000066142A3 Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
| 01/24/2002 | WO2000053168A3 Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders |
| 01/24/2002 | US20020010946 Nucleotide sequences coding enzymatic polypeptides for use in the treatment of tumors, liver disorders and alcoholism |
| 01/24/2002 | US20020010325 Complexing; purified polypeptide |
| 01/24/2002 | US20020010321 Truncated forms of NY-ESO-1 protein |
| 01/24/2002 | US20020010318 Enzyme inhibitor; for use in treatment of lung defects, asthma, bronchitis, emphysema and respiratory system disorders |
| 01/24/2002 | US20020010316 Thiazole derivatives |
| 01/24/2002 | US20020010315 Treatment or amelioration of symptoms of adult respiratory distress syndrome, septic shock, and multiple organ failure. |
| 01/24/2002 | US20020010180 Treatment of rheumatoid arthritis, Crohn's disease, acute and chronic immune diseases associated with transplantation |
| 01/24/2002 | US20020010158 Derivatives of 5-pyridylalkylphosphonates and 5-pyridylalkylmalonates useful drugs for treatment of cardiovascular related diseases and diabetes mellitus related diseases |
| 01/24/2002 | US20020010153 Oral delivery of macromolecules |
| 01/24/2002 | US20020010150 Homostatic compositions of polyacids and polyalkylene oxides and methods for their use |
| 01/24/2002 | US20020010144 Inserting wild-type therapy-sensitizing gene activity into tumor cells having mutant therapy-sensitizing gene activity and subjecting the tumor cells to a cancer therapy |
| 01/24/2002 | US20020010138 Treatment of neuromuscular disorders and conditions with different botulinum |
| 01/24/2002 | US20020010137 Methods and compositions for inhibiting neoplastic cell growth |
| 01/24/2002 | US20020010135 Having different amino acid sequence or chemically modified so the isoelectric point is lower to improve bioavailability relative the unmodified cationic polypeptide; DNA; expression vectors; transformed cells; treating neuropathies |
| 01/24/2002 | US20020010134 Peptide compositions mimicking tgf-beta activity |
| 01/24/2002 | US20020010133 Method for preventing gastritis using amylin or amylin agonists |
| 01/24/2002 | US20020010132 Compositions of muramyl peptides inhibiting the replication of hiv |
| 01/24/2002 | US20020010131 Reductive alkylation process |
| 01/24/2002 | US20020010130 Adding purified fibronectin to basic water; wound healing gels |
| 01/24/2002 | US20020010129 Stabilizing a polypeptide by shock heat treatment; peptide drugs or prodrugs such as glucagon, insulin, glucagon-like peptide (GLP) GLP-1, GLP-2, human growth hormone, Factor VII, Factor VIIa, or Factor VIIai |
| 01/24/2002 | US20020010128 Treating atopic dermatitis and/or skin photodamage, by administering a HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase) inhibitor |
| 01/24/2002 | US20020010127 Dosage form; antagonist to attenuate a side effect of said opioid agonist; analgesia for at least about eight hours when administered to human patients |
| 01/24/2002 | US20020010126 Administering an agent which antagonizes the effects of a colony stimulating factor on these monocyte/macrophage cells to lower levels or reduce their activity; treating inflammation |
| 01/24/2002 | US20020010125 Chemokinesis interferes with immune and inflammatory responses by increasing cell movements and altering cell migration patterns; interfere with spread of malignant cells through the body, and reduce inflammatory responses |
| 01/24/2002 | US20020009978 Units for displaying information on vehicles |
| 01/24/2002 | US20020009804 32705, 23224, 27423, 32700, 32712, novel human G-proteins |
| 01/24/2002 | US20020009798 Ob protein compositions and methods |
| 01/24/2002 | US20020009789 Powder containing physiologically active peptide |
| 01/24/2002 | US20020009788 Modulation of plasma membrane human leukocyte elastase |
| 01/24/2002 | US20020009786 Novel nucleic acids and polypeptides |
| 01/24/2002 | US20020009780 Design and discovery of protein based TNF-alpha variants for the treatment of TNF-alpha related disorders |
| 01/24/2002 | US20020009779 Nucleotide sequences for use in diagnosis, treatment and prevention of cancer cells; antitumor agents; prophylactic agent |
| 01/24/2002 | US20020009778 Thyroid and pituitary membrane protein |
| 01/24/2002 | US20020009777 25552, a novel human methyltransferase family member and uses thereof |
| 01/24/2002 | US20020009776 Fibroblast growth factor receptor-like molecules and uses thereof |
| 01/24/2002 | US20020009775 Polypeptide for use in treatment of diabetes, anemias, hyperplasia, restenosis and periodontal disease; antitumor agents; wound healing agents; antiischemic agents |
| 01/24/2002 | US20020009773 Nucleotide sequences coding protein associated with apoptosis; for use in treatment of defects of apoptosis and inflammation |
| 01/24/2002 | US20020009771 G protein coupled receptor proteins, their production and use |
| 01/24/2002 | US20020009764 Antitumor agents for use in treatment of cancer |
| 01/24/2002 | US20020009753 Anticoagulant test |
| 01/24/2002 | US20020009752 Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof |
| 01/24/2002 | US20020009750 Monoclonal antibodies specific to vegf receptors and uses thereof |
| 01/24/2002 | US20020009735 Mammary gland chemokine |
| 01/24/2002 | US20020009726 CD40 associated proteins |
| 01/24/2002 | US20020009715 Detecting nucleotide sequences which code cell surface protease; incubate target cells with viral display packages and detect signal from transformed cells |
| 01/24/2002 | US20020009510 Plant extracts for the treatment of increased bone resorption |
| 01/24/2002 | US20020009498 Administering nerve growth factor |
| 01/24/2002 | US20020009491 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 01/24/2002 | US20020009490 Aids; administering mixture containing germanium sesquioxide and interferon |
| 01/24/2002 | US20020009489 Atopic dermatitis treatment method |
| 01/24/2002 | US20020009461 Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases |
| 01/24/2002 | US20020009459 Fusion proteins of mycobacterium tuberculosis antigens and their uses |
| 01/24/2002 | US20020009457 Water in oil emulsion |
| 01/24/2002 | US20020009455 Prostate glands; diagnosis, therapy |
| 01/24/2002 | US20020009454 Composition and method for treating inflammatory diseases |
| 01/24/2002 | US20020009452 Method for altering undesirable immune responses to polypeptides |
| 01/24/2002 | US20020009450 Administering antagonist to surface receptors |
| 01/24/2002 | US20020009449 Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| 01/24/2002 | US20020009446 Method of modulating memory effector T-cells and compositions |
| 01/24/2002 | US20020009444 Brain disorders using monoclonal antibodies |
| 01/24/2002 | US20020009443 Binding to platelet-devived growth factor |
| 01/24/2002 | US20020009442 Diagnosis, therapy Aids |
| 01/24/2002 | US20020009441 Administering mixture of binding agent and active materials |
| 01/24/2002 | US20020009439 Central nervous system disorders therapy; genetic engineered culture; Alzheimer's disease |
| 01/24/2002 | US20020009436 Using enzymes |
| 01/24/2002 | US20020009435 Polypeptides having haloperoxidase activity |
| 01/24/2002 | US20020009434 Polypeptides having haloperoxidase activity |